Lynn Oconnor, MD
Colon & Rectal Surgery · Huntington, NYNPI 1689601767
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,881 of the $63,241 with a category attached, or 80.5%. Medical Device Business Services, Inc. accounts for 95.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $56,382 and has fallen 99.6% since, to $250 in 2025. Among colon & rectal surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $535.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$60K
- Johnson & Johnson$927
- Medtronic$603
- Dilon Technologies, Inc.$553
- Axonics, Inc.$288
- Intuitive Surgical$187
- plus $406 from 9 others
What the payments were for
- Consulting fees$50,88180%
- Travel & lodging$8,50013%
- Food & beverage$3,8596%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 69 | $60,277 |
| Johnson & Johnson(2 entities) | 7 | $927 |
| Medtronic | 8 | $603 |
| Dilon Technologies, Inc. | 9 | $553 |
| Axonics, Inc. | 4 | $288 |
| Intuitive Surgical | 3 | $187 |
| Aroa Biosurgery Incorporated | 2 | $104 |
| Ferring Pharmaceuticals Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| AbbVie | 2 | $41 |
| Innovation Technologies Inc | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $13 |
| Boston Scientific | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSEAL Product Family$53,280
- ECHELON FLEX Stapler$31,778
- STRATAFIX$27,170
- HARMONIC Product Family$27,170
- CONTOUR$25,379
- ECHELON ENDOPATH Stapler$25,379
- ETHICON ENDO-SURGERY Curved Intraluminal Stapler$25,379
- EVICEL Fibrin Sealant (Human)$758
- SURGICEL Family of Absorbable Hemostats$758
- SURGIFLO Hemostatic Matrix Family of Products$758
- HemoBlast Bellows$430
- EEA$171
- Signia$154
- Axonics$126
- INTERSTIM$125
How this compares
$63,241 in reported general payments places this provider in the 95th percentile of 177 colon & rectal surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 39 | $6,699 |
| Mesalamine | 14 | $1,902 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 22 | $1,422 |
| Hydrocortisone | 17 | $157 |
| Metronidazole | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ferring Pharmaceuticals Inc.Clenpiq | $94 | $6,69939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 colon & rectal surgery providers in New York.
Other colon & rectal surgery in Huntington
- Solomon DavidHuntington$18K
- David RivadeneiraWoodbury$271K
- Jerald WishnerMount Kisco$246K
- Sanghyun KimNew York$154K
- Ziad KronfolWest Nyack$81K
- Mehraneh JafariNew York$50K
- Jeffrey MilsomNew York$42K
- Stephen RauhRochester$37K
- Evelyn IrizarryBronx$26K
- David SchwartzbergNew York$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.